Table 3.
Demographic and clinical data of IBD patients and controls.
| Crohn's disease | Ulcerative colitis | Controls | |
|---|---|---|---|
| N | 49 | 34 | 96 |
|
| |||
| Number of participants | 41 | 28 | 67 |
| Sex (M/F) | 22/19 | 15/13 | 38/29 |
| Age (range)* | 32 (18–50) | 32.5 (18–49) | 32 (18–50) |
| Disease duration in years (range)* | 3 (0.1–21) | 5 (0.1–20) | |
| Patients on oral steroids the past year (%) | 17 (41.4) | 11 (39.2) | |
| Joint Hypermobility (%) | 29 (70.3) | 10 (35.7) | 17 (25.4) |
| Median Beighton Scores [range] | |||
| In total population | 4 [0–9] | 3 [0–8] | 2.5 [0–9] |
| In hypermobile subjects | 5 [4–9] | 5 [4–8] | 5 [4–9] |
| Articular Manifestations (%) | |||
| Spondylarthropathy (SpA)† | 5 (12.2) | 7 (25) | |
| Hypermobility Syndrome (HMS) | 5 (12.2) | 1 (3.57) | |
| Overlap symptoms (SpA & HMS) | 7 (17.1) | 0 | |
| Non specific or Degenerative Symptoms | 11 (26.8) | 7 (25) | |
| Patients excluded from the study | |||
| Age restriction | 5 | 5 | |
| Spondylarthropathies (AS) | 3 | 1 | |
*Data are expressed as medians along with minimum and maximum values.
†Arthritis which does not influence the Beighton score counting.